Fred Hutchinson Cancer Center

Dr. Elizabeth Halloran, expert in vaccine trial design and quantitative methods for infectious diseases, transitions to emerita

Pioneering biostatistician and infectious disease expert Dr. Elizabeth Halloran recently transitioned to emerita after a ...

Top Sunglasses Manufacturer Signals Shift Toward Premium, Customized Eyewear

SHENZHEN, GUANGDONG, CHINA, January 16, 2026 /EINPresswire.com/ -- The global sunglasses industry continues to ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATE ...

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027Data from the ongoing parallel BROADEN2 Phase 2b atopic ...

Enlighten Clinical Solutions Announces Official Release of Integrated eTMF Module

New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial ...
IEEE

Two-Timescale Cross-Layer Design for URLLC Over Parallel Fading Channels With Imperfect CSI

Abstract: This paper investigates the cross-layer design for point-to-point ultra-reliable low latency communication (URLLC) over parallel fading sub-channels by jointly considering channel estimation ...